Audited Financial Results for the quarter and year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ANG Lifesciences India Ltd reported FY2026 standalone revenue of Rs 9,160.45 lakhs, a marginal increase of 1.9% from Rs 8,991.01 lakhs in FY2025. The company continues to incur losses with standalone loss after tax of Rs 472.64 lakhs, significantly improved from Rs 1,034.29 lakhs loss in the previous year. Consolidated loss after tax stands at Rs 1,108.48 lakhs. The auditors issued an unmodified opinion but included an Emphasis of Matter highlighting several concerns: default in repayment of HDFC Bank borrowings totaling Rs 2,586.45 lakhs outstanding as of March 31, 2026; non-deposit of statutory dues including ESI, PF, and TDS for over six months; pending income tax disputes including Rs 453.95 lakhs for subsidiary Mansa Print and Publishers; and GST ITC reversal liability of Rs 12.20 lakhs. The company has not appointed an internal auditor as required under Section 138 of Companies Act 2013.
The company shows improving operational performance with reduced losses, but faces serious liquidity stress evidenced by loan defaults and unpaid statutory dues. Shareholders should monitor the company's ability to service its debt obligations and resolve regulatory compliance issues.